Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

Kalaris enrolling phase 1b/2 study of TH103 for nAMD | Ophthalmology Times

(Image credit: ©kwanchaift/AdobeStock) Kalaris Therapeutics announced the company is currently enrolling a phase 1b/2 multiple ascending dose (MAD) study of TH103 for the treatment of neovascular age-related macular degeneration (nAMD).1 “The phase 1b/2 study represents an important milestone in advancing…

Timothy Lai on the SALWEEN trial

Photo of Timothy Lai, MD, at EURETINA 2025 in Paris, France Timothy Lai, a clinical professor honorary at the Department of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong, presented the one-year data from the Salween study…

Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye

To learn more about or to register for EyeCon 2025, click here. Set against the backdrop of a scenic Florida coastline and a growing emphasis on cross-specialty collaboration in eye care, the Ophthalmology Times and Optometry Times EyeCon® 2025 conference is…

Stay informed and not overwhelmed, subscribe now!